undamentalytics Newsletter

Dulac Edward J III: insider trades

Chief financial officer at 2 companies we cover. No open-market purchases and 9 sales not made under a pre-set plan, reported from August 20, 2021 to July 24, 2026.

What happened after Dulac Edward J III’s sales?

After their sales, the shares moved −60.4% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Dulac Edward J III: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 7 +7.2% −1.7% 57% 5 0.53 0.63 No reliable evidence
Sales, 12 months after the report 5 −60.4% −52.2% 100% 4 −4.78 0.017 Some evidence: seller right
Sales, 12 months after the trade 5 −63.5% −63.4% 100% 4 −5.82 0.010 Some evidence: seller right

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Fate Therapeutics Inc FATE Chief Financial Officer06August 20, 2021January 10, 2024
Intellia Therapeutics, Inc. NTLA EVP, Chief Financial Officer03July 25, 2025July 24, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
July 24, 2026July 22, 2026 NTLA Sale $91,249 +2.0%not yetnot yet
January 7, 2026January 5, 2026 NTLA Sale $58,751 +29.4%not yetnot yet
July 25, 2025July 23, 2025 NTLA Sale $104,617 +88.6%−33.4%−42.5%
January 10, 2024January 9, 2024 FATE Sale $30,712 not yetnot yetnot yet
August 21, 2023August 18, 2023 FATE Sale $13,210 not yetnot yetnot yet
January 11, 2023January 10, 2023 FATE Sale $38,414 −1.7%−44.5%−42.8%
August 19, 2022August 18, 2022 FATE Sale $153,051 −27.4%−99.6%−95.3%
January 13, 2022January 11, 2022 FATE Sale $85,757 −12.6%−72.2%−73.5%
August 20, 2021August 19, 2021 FATE Sale $306,602 −27.7%−52.2%−63.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Dulac Edward J III traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.